Fairmount Funds Management LLC Viridian Therapeutics, Inc.\De Transaction History
Fairmount Funds Management LLC
- $628 Million
- Q1 2024
A detailed history of Fairmount Funds Management LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Fairmount Funds Management LLC holds 1,845,813 shares of VRDN stock, worth $22.7 Million. This represents 5.15% of its overall portfolio holdings.
Number of Shares
1,845,813
Previous 1,369,623
34.77%
Holding current value
$22.7 Million
Previous $29.8 Million
8.35%
% of portfolio
5.15%
Previous 4.09%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$61.9 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$55.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$47.8 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$46.9 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$45 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $491M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...